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Abstract: The treatment of chronic lymphocytic leukemia (CLL) has evolved over the 
last few decades. Recognition has increased of several key components of CLL biology 
  currently manipulated for therapeutics. A milestone in the treatment of CLL was reached 
with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/
cyclophosphamide/rituximab combination has demonstrated survival advantage for the first 
time in the treatment of CLL. Several other biological compounds are being explored with 
the hope of improving responses, impacting survival, and ultimately curing CLL. Important 
agents being tested are targeted on CLL surface molecules and their ligands, signal transduction 
protein and oncogenes. This review provides a brief summary of the recent advances made in 
preclinical and clinical investigation of selected promising therapeutic agents, which lead the 
target-directed therapeutic approach.
Keywords: CLL, Akt inhibitors, Bcl-2 inhibitors, cyclin d kinase inhibitors, heat shock protein 
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Introduction
Chronic lymphocytic leukemia (CLL) is one of the most common forms of leukemia 
in the Western hemisphere with an annual incidence of 5.17 per 100,000 person-
years.1 CLL is a heterogeneous disease carrying a variable clinical course among 
patients; some are monitored without any treatment, while others develop symptoms 
and require therapeutic intervention.2 Historically, treatment options for patients with 
CLL include either a nucleoside analog (fludarabine) or an alkylating agent (chloram-
bucil). This approach has now been surpassed by the combination regimens such as 
fludarabine and cyclophosphamide (FC), or more recently by the addition of rituximab 
to FC (FCR).3,4 Such a chemo-immunotherapy approach has significantly improved 
response rates as well as progression-free and overall survival.5 Additionally newer 
chemotherapeutics such as bendamustine have also become available with successful 
clinical outcomes. Unfortunately all patients eventually relapse and CLL remains an 
incurable cancer. However, the dilemma continues for relapse and refractory disease, 
calling for insight into disease biology and development of new treatments for improved 
clinical outcome.
Biology of CLL cells
CLL cells are mature B-cells that express CD5, CD19, and CD23 with low levels of 
immunoglobulins (IgM, IgD) on the cell surface.6 These malignant cells are mostly OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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arrested in the G0 phase of the cell cycle and are marked by 
significant deregulation of apoptosis.7 CLL cells proliferate in 
the lymphoid tissues and bone marrow whereas in the blood 
they stay dormant.8 Clonal proliferation of the malignant 
B cell clone also induces cellular immune defects including 
altered CD4/CD8 ratio of T effector cells, functional 
deficiency of CD40 ligand, and an increase in the number 
of immune inhibitory T regulatory cells. Animal models 
infused with CLL leukemic cells have also demonstrated 
similar T cell defects.9 The transgenic mouse models of 
CLL demonstrated acquisition of changes in multiple T-cell 
pathways regulating antigen recognition and effector function 
with a reversible immunological synapse dysfunction. The 
majority of altered genes in the CD4 T cells are involved in 
cell proliferation, differentiation, and cytokine/chemokine 
response pathways. The B-cell receptor (BCR) plays a 
significant role in disease biology by engaging costimulatory 
molecules, protein tyrosine kinases, as well as the zeta 
associated protein-70 which activates signaling pathways 
such as p38, c-jun N terminal kinase, extracellular-regulated 
kinase, and the phosphoinositide 3-OH kinase (PI3K/
PKC/AKT).10 The signal transduction pathways such as 
the vascular endothelial growth factor (VEGF) mediated 
CD40-CD40L and/or signal transducer and activator of 
transcription 3 interacts with the prosurvival cytokines 
from the microenvironment to promote leukemic cell 
proliferation.11,12 Interaction of the CLL cell with components 
of the microenvironment as well as the inherent biological 
characteristics of the leukemic clone induces upregulation 
of antiapoptotic proteins that provides additional support to 
the survival of the CLL cell.13 Additionally, specific genetic 
lesion(s) such as trisomy 12 (associated with p27, CDK4, 
and Bax overexpression); del(13q) (causing increased 
levels of protein kinase B Akt); and the del(11q) results in 
decreased synthesis of ataxia telengiectasia mutated (ATM) 
and del(17p) results in p53 dysfunction. The ultimate result 
is activation of molecular pathways responsible for CLL cell 
survival and drug resistance.12 Identifying these molecular 
markers has elucidated the development of new treatment 
modalities, some of which are discussed here.
Application of disease biology  
in therapeutics
Improved understanding of the biological processes involved 
in CLL through specific cell surface molecules and their 
ligands or downstream molecular events mediated through 
signal transduction proteins has enabled development of new 
targeted therapeutics. These newer agents can potentially 
suppress and disrupt the signaling cascade(s) either through 
interacting with the tumor cell surface, intracellular proteins 
or organelles, or interruption of translational events directed 
by tumor specific oncogenes.
In CLL, target directed therapeutic strategies incorporate 
maneuvers to manipulate the components of the tumor 
microenvironment, engagement of cell surface molecules 
(such as CD19, CD20, CD25, CD52, CD40, and TRAIL), or 
interruption of intracellular processes (such as those mediated 
through the Bcl-2 family of proteins, Akt, proteosome, or the 
heat shock proteins).14–16
Targeting the microenvironment
immunomodulatory drugs
Deregulation of the host immune response is an important 
step in cancer progression. Ongoing research has revealed that 
this deregulation of the host immune response is a multistep 
process that includes failure of tumor cells to express immune 
activating antigens, downregulation of major histocompatibility 
complex, and/or failure to express costimulatory ligands that 
normally engage corresponding receptors on T cells for a 
host-directed immune response.17 Tumor cells adulterate 
the microenvironment through manipulation of host cells in 
aberrant production of prosurvival cytokines, which either 
directly promote growth of the leukemic cell via activation of 
specific signaling pathways or induce an immune suppressive 
milieu fostering unchecked CLL cell proliferation.13,18,19 It has 
been demonstrated that interaction between tumor cells in the 
lymph nodes and microenvironment results in upregulation 
of BCR-regulated genes resulting in NFκB activation.20 
The net effect is a persistent and uninterrupted growth of 
malignant CLL clone with progressive decline in immune 
surveillance.
Mechanism of action
Thalidomide and lenalidomide are a newer class of anticancer 
agents that belong to the group of immunomodulatory drugs 
(IMiDs). This group of drugs has the ability to manipulate 
components of the tumor-supporting microenvironment.21 
They uniquely affect multiple targets within the malignant 
microenvironment thus altering the endogenous support 
mechanism of the malignant clone. Both thalidomide and 
lenalidomide were shown to downregulate critical prosur-
vival cytokines such as the VEGF, interleukin (IL)-6, tumor 
necrosis factor (TNF) α, and platelet-derived growth factor 
that are involved in CLL cell proliferation and survival.22 
Furthermore, they can also alter the leukemic cell phenotype 
by modulating the expression of surface antigens (such as OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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CD80, CD86, and CD40), thereby contributing to improved 
immune directed tumor cell killing.19,22 Recently, IMiDs have 
also been reported to enhance T and NK (natural killer) cell 
recognition of CLL cells thereby directing killing of the 
leukemic cell.23 Collectively these observations   demonstrate 
that IMiDs treatment is focused on modulating the   elements 
of the tumor microenvironment and at the same time 
modulating surface antigen (upregulation of CD80, CD86, 
and CD40) of the leukemic cells resulting in the reduction 
of tumor burden.
Thalidomide was first investigated in combination 
with fludarabine in patients with treatment naïve CLL.24 
Thalidomide (100 mg, 200 mg, and 300 mg) every day orally 
was given with fludarabine (25 mg/m2 intravenously for 
5 days every 4 weeks) for 6 months. Overall the combination 
of fludarabine and thalidomide was well tolerated, fatigue 
(76.9%), constipation (61.5%), and peripheral sensory 
neuropathy (61.5%) being the most frequently observed 
toxicities. Common hematological toxicities of this 
  combination included thrombocytopenia (54%), anemia 
(38%), and neutropenia (31%). Tumor flare reaction (TFR) 
was noted in (46%) of the patients. However, all the patients 
who developed flare were able to complete scheduled 
treatment. Two patients developed pulmonary embolism.24 
The overall response rate (ORR) of this combination was 
100% with complete remission (CR) rate of 57%. This 
observation was further confirmed in another study conducted 
among patients with high-risk CLL.25 In this clinical trial 20 
patients with treatment-naïve (Arm A) and 20 patients with 
previously treated (Arm B) CLL were enrolled; 13 patients 
had a high-risk cytogenetic profile and 36 had mutated 
IgVH.   Thalidomide was administered at 100 mg/day, with 
fludarabine given at 25 mg/m2 intravenously every day for 
5 days on a 4-week cycle for a maximum of six cycles. As 
anticipated, responses were higher in Arm A vs Arm B with 
an ORR and CR rate of 80% and 25% vs 25% and 0%, 
respectively. Thalidomide and fludarabine combination was 
also noted to demonstrate efficacy in high-risk cytogenetic 
CLL patients with an ORR of 39%. Common toxicities 
included constipation (95%), fatigue (100%), and infectious 
complications (45%). TFR was recorded in a total of ten 
patients but all of these side effects were of moderate 
intensity.25 In another clinical trial conducted by Kay et al 
the clinical activity of thalidomide alone was evaluated in 
patients with relapsed or refractory CLL.26 In contrast to the 
other studies, TFR was the major toxicity reported in this 
study, warranting discontinuation of therapy in most patients 
and eventually early termination of the study due to lack of 
accrual. ORR and CR of thalidomide alone in this patient 
population were 11% and 4%, respectively. Based on this 
study, the activity of single-agent thalidomide in patients with 
relapsed CLL is considered suboptimal due to low response 
rates, although 78% of patients demonstrated decrease 
in peripheral blood leukemic counts on treatment with 
thalidomide.26 These clinical trials set the stage for evaluation 
of the more potent thalidomide analog, lenalidomide.
Lenalidomide was first evaluated in relapsed or relapsed 
and refractory CLL patients through a phase II clinical trial.27 
Important patient characteristics included median of three 
prior therapies (51% fludarabine refractory), with advanced 
Rai stage disease in 64% of the patients. The starting dose 
in the initial cohort of patients (n = 29) was 25 mg/day, but 
due to high incidence of hematological toxicities subsequent 
patients (n = 16) were started at a lower dose of lenalidomide 
(10 mg/day) with dose escalation of 5 mg/day every 2 weeks 
as tolerated to a maximum of 25 mg/day. The study schema 
allowed addition of rituximab (375 mg/m2) when patients 
progressed on lenalidomide alone. The ORR of single-agent 
lenalidomide in this patient population was 57%, 9% of 
patients achieving CR. Clinical responses were observed 
irrespective of high-risk (47%) or bulky disease (40%).28 
Hematological toxicities reported include neutropenia in 76% 
and thrombocytopenia in 51% of patients respectively. TFR 
is an important side effect of IMiDs therapy previously not 
known and seems to be predominantly noted in patients with 
lymphoproliferative disorder. The phenomenon is suggestive 
of host immune activation mimicking an inflammatory 
response.29 The overall incidence of TFR was 67%, with 
grade 3 TFR noted among 10% of the patients.30 We also 
observed tumor lysis syndrome in 5% of patients.31
A subsequent phase II clinical trial, led by Ferrajoli and 
colleagues, validated the primary observation made with 
lenalidomide in CLL.32 This phase II trial also focused 
on patients with relapsed CLL with the starting dose of 
lenalidomide at 10 mg given every day continuously. The 
dose of lenalidomide was escalated by 5 mg every 28 days 
to a maximum of 25 mg/day. The ORR reported in this 
clinical trial was 32%, with CR rate of 7%. Responses were 
observed in CLL patients with high-risk cytogenetics (ORR 
31%) or unmutated IgVH (24%) or those with fludarabine-
refractory disease (25%).33 Recent clinical investigation is also 
focusing on the use of lenalidomide in previously untreated 
CLL patients either alone or in combination with other anti-
CLL therapeutics.34,35 Chen et al evaluated the efficacy of 
lenalidomide in treatment naïve patients with CLL.34 The 
study enrolled 25 patients with a median age of 60 years OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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(range 33–78); 44% of patients had Rai stage III/IV disease, 
36% had bulky lymphadenopathy and adverse cytogenetics 
(17p or 11q) were noted among 32% of patients. The study 
schema allowed for an initial starting dose of 10 mg once 
daily with weekly escalation of 5 mg to a maximum tolerated 
dose (MTD) of 25 mg/day for 21 days of a 28-day cycle. Due 
to severe complications (tumor lysis in one patient requiring 
dialysis and death of another patient from neutropenic sepsis) 
the study was amended to an initial starting dose of 2.5 mg 
and a slower escalation to a 10 mg target dose. Important 
drug-related toxicities include grade $3 neutropenia (43% of 
patients) and thrombocytopenia (13% of patients). TFR was 
recorded in (80%) of the patients (all reported as grade 1–2). 
ORR was 65%, eleven patients achieving partial response 
(PR).36 Collectively these studies confirmed the clinical 
effectiveness of lenalidomide as a single agent in patients with 
CLL. Ongoing phase III studies are investigating the role of 
lenalidomide as monotherapy in previously untreated CLL.
Preclinical evaluations suggest that lenalidomide may be 
an important partner with immunotherapeutics. Ferrajoli et al 
reported the clinical efficacy of lenalidomide in combination 
with rituximab in relapsed CLL. Rituximab was administered 
375 mg/m2 weekly (days 1, 8, 15, 22) and then once every 
month from cycle 3–12 on a 4-weekly schedule along 
with lenalidomide 10 mg every day beginning day 9 of the 
first treatment cycle. The study enrolled 60 patients with 
a median age of 59 years (range 44–83) with median of 2 
prior treatments range (1–9). Advance stage (Rai stage III/
IV) was noted in 41% of the patients, high-risk disease as 
defined by unmutated IgVH and del(17p) was present in 70% 
and 24% of patients, respectively. ORR was 68% without 
any CR.35 Recently results of lenalidomide in combination 
with ofatumumab were also reported. The study evaluated 
the combination of immune therapies in relapsed CLL. 
Important characteristics include median age of 62 years 
(range 45–82), median of 2 (range 1–8) before treatment, 
25% had fludarabine refractory, 31% had del(17p) and 19% 
had del(11q). Ofatumumab was administered intravenously 
weekly for 4 consecutive weeks (300 mg week 1, 1000 mg 
week 2, and all subsequent doses, then monthly for months 
2–6 and then once every 2 months for months 7–24). 
Lenalidomide was given orally at 10 mg daily starting on 
day 9 and continued daily. Adverse side effects included 
grade $3 anemia (13% of patients) and neutropenia (50% of 
patients). TFR grade 1–2 was noted among 13% of patients. 
ORR reported was 63%, with 13% CR and 50% PR.37
Tumor cell microenvironment remains an important 
therapeutic target, and manipulation of the microenvironment 
using the IMiDs has demonstrated impressive clinical 
activity. Furthermore, combination of these molecules 
with chemotherapeutics or immunotherapeutics has also 
  significantly improved clinical responses even in patients 
with cytogenetic features of high-risk disease.
Targeting the surface molecule
Monoclonal antibodies
The unique antigens present on the CLL cell surface have 
enabled development of additional therapeutic targets. The 
successful surface targets therapeutically exploited include 
the CD20 and CD52 antigens for which therapeutic mono-
clonal antibodies (rituximab and alemtuzumab respectively) 
have proven clinical efficacy, resulting in US Food and Drug 
Administration (FDA) approval. The success of the mono-
clonal antibodies (mAb) in CLL has resulted in exploitation 
of new targets on the CLL clone including CD19, CD25, 
CD40, CD37, and Apol/TRAIL as well as novel epitopes on 
the CD20 molecule.
Mechanism of action
The precise mechanism of action of mAb in killing cancer 
cells is variable and depends on the target antigen as well as 
the potential role of the mAb in response to the host immune 
system. Some of these mAbs execute direct tumor cell killing 
by activating effector mechanisms such as complement 
dependent cytotoxicity (CDC), antibody-dependent cellular 
cytotoxicity (ADCC), while others are tumoricidal as a 
result of directly providing apoptotic intracellular signals.38 
The mAbs have also demonstrated ability to enhance the 
sensitivity of tumor cells in combination with traditional 
chemotherapies, resulting in significant improvement in 
clinical effects. Some of the clinically relevant mAbs are 
discussed here (Table 1).
Targeting CD20
CD20 is an important antigen expressed by B cell lympho-
proliferative disorders including CLL. Rituximab is a chimeric 
anti-CD20 mAb, which has shown efficacy in patients with 
CLL. The activity of single-agent rituximab in CLL is modest 
at standard doses with ORR from 15% to 25%.39 O’Brien 
et al reported a dose–response association with an ORR of 
40%; 22% in 500–825 mg/m2, 43% in 1000–1500 mg/m2, 
and 75% in 2250 mg/m2 (P = 0.007).40 The major impact 
of targeting the CD20 has been shown in combination with 
conventional chemotherapy. This has resulted in improved 
ORR, CR rate, and survival advantage.41 In this context the 
most effective combination strategy is the FCR regimen, as OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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reported by Keating et al, Wierda et al, and Tam et al.5,42,43 
This   combination resulted in ORR and CR rates of 95% and 
72%, respectively. Hallek et al recently reported a follow-up 
study comparing this chemoimmunotherapy regimen with 
chemotherapy-only combination (FC).44 This phase III clinical 
study confirmed the benefit of adding anti-CD20 mAb and 
thus the importance of target-specific therapy in patients with 
CLL. The impressive results of incorporating target directed 
anti-CD20 mAb into anti-CLL treatment regimens has fueled 
the development of several new mAbs including new anti-
CD20 molecules (ofatumumab, afutuzumab, veltuzumab) 
with improved target binding (Table 1).45
Ofatumumab (HuMax-CD20) is a fully humanized mAb, 
also designed to target the CD20 molecule on CLL cells. 
In comparison with rituximab, ofatumumab recognizes a 
novel epitope on the CD20 molecule that is localized in the 
second extracellular loop, distinct from the site recognized by 
rituximab. Ofatumumab has demonstrated superior antitumor 
effects in vitro with the ability to induce CDC in rituximab 
resistant cells.45,46 Fludarabine refractory disease remains a 
challenging group among CLL patients with limited treatment 
options. In an international multicenter study (n = 138) 
clinical activity of ofatumumab was evaluated in patients 
with fludarabine and alemtuzumab refractory disease.47 The 
patient population evaluated in this trial included a group 
with refractory disease to both fludarabine and alemtuzumab 
therapy (FA-ref) (n = 59) and another group with bulky 
disease refractory to fludarabine therapy (BF-ref) (n = 79). 
Other important clinical characteristics include median of 
five and four prior therapies, advanced Rai stage III and 
IV among 54% and 69% of patients, high-risk cytogenetics 
del(17p) and del(11q) were noted among 28% and 17%, and 
40% and 27%, in the FA-ref and BF-ref groups, respectively. 
Ofatumumab was administered intravenously weekly for 8 
weeks followed by monthly infusions for 4 months for a total 
of 24 weeks (dose 1 = 300 mg, doses 2–12 = 2000 mg). The 
study demonstrated activity of ofatumumab in FA-ref as well 
as BF-ref patients with ORRs of 58% and 47%, respectively. 
CR was also reported in one patient. Patients with del(17p) 
were noted to have lower responses. The median progression-
free survival and overall survival were 5.7 and 5.9 months, 
and 13.7 and 15.4 months, in the FA-ref and BF-ref groups, 
respectively. The most common toxicities during treatment 
were infusion-related reactions (∼60%) and infections (74%). 
Updated results showed ORR of 51% for the FA-ref group and 
44% for the BF-ref group.48 These results formed the basis for 
Table 1 Monoclonal antibodies in CLL
Study Patient population Treatment regimen Response (%)  Median DOR 
(months) OR CR PR
O’Brien et al40 Relapsed CLL Rituximab dose escalation 36a 0 36 8
Tam et al43 Untreated CLL Fludarabine, cyclophosphamide,  
rituximab (FCR)
95 72 10b 80
wierda et al48 Relapsed CLL Ofatumumab single agent 58c 
47
0  
1
58  
47
5.7d and 5.9
wierda et al49 Untreated CLL Ofatumumab, fludarabine, 
cyclophosphamide (O-FC)
77e 
73
32f 
50
NR  
NR
Not reached
Morschhauser et al51 Relapsed CLL Afutuzumab single agent 62 1g 7h Not reached
Morschhauser et al53 Relapsed non-Hodgkin’s 
lymphoma
veltuzumab single agent 0 0 0 Not reached
Osterborg et al56 Relapsed CLL Alemtuzumab single agent 42 4i 38 12
Nabhan et al57 Relapsed CLL Alemtuzumab and rituximab  
combination*
52 8 40j 6
Furman et al64 Relapsed CLL Dacetuzumab single agent NR 0 0k NR
woodworth et al66 Relapsed CLL Lumiliximab NR 0 0l NR
Byrd et al67 Relapsed CLL Lumiliximab in combination  
with FCR
71 48 10 NR
Frankel et al71 Relapsed CLL Ontak single agent NR 0 17m NR
Notes: aOR was 36% and ranged between 22% and 75%; bPR nodular in 10%, PR due to cytopenias in 7%, and PR with residual disease in 6%; c,dOR were 58% and 47% in the 
FA-ref and BF-ref groups, 1 CR in the BF-ref group otherwise all responses were PR, median duration of response was 5.7 months in the FA-ref group and 5.9 months in the 
BF-ref group; e,fOR was 77% and CR was 32% for group A receiving ofatumumab at 500 mg after initial dose of 300 mg in combination with fludarabine and cyclophosphamide, 
OR was 73% and CR was 50% for group B receiving ofatumumab at 1000 mg after initial dose of 300 mg in combination with fludarabine and cyclophosphamide; both groups 
received total of 6 cycles; g,hCRi 1 and 7 PR was reported; iCR attained in bone marrow in 36% of patients; jalemtuzumab was given at escalating dose to a maximum of 30 
mg in combination with rituximab, PR 40% and partial remission nodular (PRn) was 4%; kNo patients achieved objective response, 5 patients demonstrated stable disease; 
lreductions in lymphocyte counts were noted in 91% and reduction in size of lymph nodes was noted in 59% of patients; mPR was reported as 17% and 58% minimal responses, 
progression free interval in responders ranged between 1 and 19+ months.
Abbreviations: CR, complete response; CCL, chronic lymphocytic leukemia; DOR, duration of response; NR, not reported; OR, overall response; PR, partial response.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Masood et al
approval of ofatumumab for CLL patients with fludarabine/
alemtuzumab-resistant disease. Ofatumumab has also been 
evaluated in combination with FC as front-line treatment.49 
Wierda et al reported the efficacy of two doses of ofatumumab 
(500 mg; group A or 1000 mg; group B) in combination with 
FC regimen. ORR and CR rates were 77% and 73% in group 
A and 32% and 50%, respectively.49 (Table 1).
Afutuzumab (GA-101) is a third-generation humanized mAb 
developed for the treatment of B cell malignancies. Afutuzumab 
is the first glycol engineered, type II anti-CD20 mAb to enter 
into phase I/II clinical trials. Afutuzumab works by binding to 
the type II epitope localized in the CD20 extracellular loop, 
causing enhanced direct cell apoptosis and ADCC.50 The clinical 
activity of afutuzumab has been demonstrated in relapsed CLL. 
The important patient characteristics included a median of three 
prior treatments, high-risk cytogenetic del(17p) or del(11q) 
in 33% of patients, and 70% of patients had unmutated IgVH. 
Afututzumab was administered at 400–2000 mg intravenously 
in a safety driven dose-escalating design on days 1, 8, and 22 
repeated every 3 weeks for a total of nine infusions. The drug 
demonstrated antileukemic activity as manifested by depletion 
of B cells following the first infusion. The ORR was 62% with 
1 CR and 7 PR.51 Grade 1–2 toxicities were infusion-related 
reactions including fever, chills, hypotension, and nausea, 
which were manageable with steroids. Grade 3–4 hematological 
events included transient neutropenia in nine patients, febrile 
neutropenia in one, and one patient was reported to develop 
transient thrombocytopenia.51 Veltuzumab is a humanized 
second-generation anti-CD20 mAb with structural similarities 
to rituximab, except for a single amino acid difference in the 
CDR3-VH region. Veltuzumab is currently under development 
for the treatment of B cell lymphoproliferative disorders.52 
Veltuzumab has shown modest activity in a small cohort 
of CLL patients. However, in preclinical studies this agent 
showed favorable data and efficacy in lymphoproliferative 
disorders.52–54
Targeting CD52
Alemtuzumab is a humanized mAb that targets CD52 antigen. 
The antiproliferative effects of alemtuzumab are postulated to 
act mainly via CDC and ADCC, although the exact mechanism 
remains to be defined. Alemtuzumab was approved by the 
FDA based on a pivotal trial, which demonstrated its efficacy 
in patients with fludarabine-refractory CLL.55 In a pivotal 
trial of relapsed CLL alemtuzumab was administered at 
3 mg in dose escalation to 30 mg intravenously three times 
weekly for a maximum of 12 weeks (n = 93). Prophylaxis 
with co-trimaxazole and acyclovir was mandatory. The 
study demonstrated efficacy, with an ORR of 33% (CR 
2%; PR 31%) with overall median survival of 16 months 
and median survival for responders reported as 32 months. 
Most commonly encountered adverse events were infusion-
related and included grade ,2 rigors and fevers. Infectious 
complications reported were grade 3–4 infections in 26.9%, 
cytomegalovirus reactivation in seven, grade 2 infection in 
three, and grade 3 infections in four patients.55 Similarly 
activity of alemtuzumab in relapsed CLL was demonstrated 
by Osterborg et al, with an ORR of 42%, 4% of patients 
achieving CR and 38% PR. Important hematological toxicities 
included grade 4 neutropenia in 10% and thrombocytopenia 
in 7% of patients. Infectious complications included two 
opportunistic infections and four bacterial septicemias. 
Infusion-related toxicities such as fever and rigors were also 
reported in the first week of administration and were easily 
managed with anti-inflammatory medications.56 Combination 
of alemtuzumab with other mAbs and cytotoxic agents has 
also been reported but efficacy was variable.57 An important 
limitation of alemtuzumab seems to be limited efficacy in 
patients with bulky disease, the underlying mechanism of 
which remains unknown. Hillmen et al reported the clinical 
efficacy of alemtuzumab in previously untreated CLL patients 
in a randomized phase III trial (CAM 307).58 Patients were 
randomized to receive either alemtuzumab (30 mg three times 
weekly for 12 weeks) or oral chlorambucil (40 mg/m2 every 
28 days for a maximum of 12 months). The ORR reported 
with alemtuzumab was 83% with 24% CR, whereas the ORR 
in the chlorambucil group was 55% with 2% of patients 
attaining CR. The incidence of adverse events was comparable 
between both the groups, with infusion-related toxicity and 
cytomegalovirus infection being higher for the patients taking 
alemtuzumab.58 Alemtuzumab has demonstrated significant 
activity in patients with the del(17p). This effect is not 
as readily observed with other monoclonal antibodies or 
nucleoside analogs. Currently, alemtuzumab remains the only 
FDA-approved agent available with activity in patients with 
del(17p) who lack function of the p53 gene (Table 1).59
Targeting CD19
XmAb5574 is a novel engineered anti-CD19 mAb with 
a modified constant fragment (Fc)-domain designed to 
enhance binding of FcγRIIIa. The mechanism of action 
includes potent ADCC. The ADCC is mediated by NK cells 
through a granzyme B-dependent mechanism. Preclinical 
data appear promising and are associated with significant 
activity in CLL. It is currently being evaluated in a phase I 
clinical trial (Table 2).60OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Targeting CD37
CD37 is a member of the tetraspanain family involved 
in regulation of key cellular functions such as activation, 
proliferation, and cell–cell adhesions. TRU-016 is a novel 
small compound that targets CD37 and induces cell killing 
by augmenting the functions of NK cells and inducing 
Fc-mediated cellular cytotoxicity. TRU-016 has been 
investigated in patients with relapsed CLL.61,62 This phase 
I study included 57 patients of median age of 66 years, Rai 
stage III–IV disease was present in 68.5%, and high-risk 
cytogenetics del(17p) or del(11q) were present in 38% 
and 21% of the patients, respectively.61 TRU-016 was 
administered in nine doses, which ranged from 0.03 to 20 mg/
kg intravenously once a week for 4–12 doses followed by 
second schedule doses of 3, 6, or 10 mg/kg on days 1, 3, and 
5 on the first week followed by 3–11 weekly doses. MTD was 
not reached. Important toxicities included febrile neutropenia 
(3), pneumonia (3), infusion reactions (2), pyrexia (2), and 
(2) dyspnea. Neutropenia was reported as the dose limiting 
toxicity. Updated results demonstrated that patients with one 
or two prior therapies demonstrated a superior ORR of 44%.61 
Patients with .3 prior treatments failed to demonstrate any 
objective responses except for reduction in lymphocyte count 
of 67% (Table 2).61
Targeting CD40
CD40 is a member of the TNF family expressed on normal 
and malignant B cells. Dacetuzumab (SGN-40) is a human-
ized mAb against CD40. Dacetuzumab has shown activity in 
relapsed non-Hodgkin’s lymphoma (NHL).63 A preliminary 
phase I study demonstrated clinical activity in patients with 
lymphoproliferative disorder. The study schema included 
50 patients with relapsed B-cell NHL (diffuse large B cell 
42%, follicular 24%, mantle cell 20%, small lymphocytic 
lymphoma 2%, other 6%) with a median of three prior 
treatments (range 1–8). Dacetuzumab was administered 
intravenously from 2 mg/kg weekly for 4 weeks to dose 
escalation of 8 mg/kg to different patient cohorts. MTD was 
not established at the dose levels tested. Reported side effects 
in .20% of patients were fatigue, pyrexia, and headache, and 
noninfectious inflammatory eye disorder occurred in 12% of 
patients. The ORR observed in these patients was 12% with 
1 CR and 5 PR.63 Additionally, there was no dose–response 
relationship. Furman et al reported a phase I study of dacetu-
zumab in relapsed CLL.64 This study included twelve patients 
with relapsed CLL who had received a median of four prior 
treatments (range 2–11). The patients were administered 
dacetuzumab starting at 3–8 mg/kg in a dose escalation 
manner. The most common adverse effects were fatigue, 
headache, anorexia, conjunctivitis, hyperhidrosis, and night 
sweat. Although no objective response was identified, 41% 
of patients showed stable disease (Table 1).64
Targeting CD23
Lumiliximab is a primatized monoclonal antibody that 
targets the CD23 antigen and mediates a ADCC and CDC.65 
Lumiliximab has demonstrated antileukemic activity in 
CLL. In a phase I trial for patients with relapsed CLL, 
lumiliximab demonstrated decrease in lymphocyte counts 
in 91% of patients and reduction in lymphadenopathy in 
59% of patients.66 This was followed by a phase I/II trial in 
which lumiliximab was given in combination with the FCR 
regimen to patients with relapsed CLL.67 This study enrolled 
31 patients and lumiliximab was administered at 375 mg/m2 
(n = 3) or 500 mg/m2 (n = 28) in combination with FCR for 
six cycles. ORR was 71%, 48% of patients showing CR 
and 10% achieving PR (Table 1).67–69 The most common 
side effects were nausea and pyrexia. Although the initial 
results were promising, subsequent studies did not validate 
the findings and an ongoing international multicenter phase 
III trial (LUCID) was halted due to the lack of efficacy of 
lumiliximab.
Targeting CD25 (iL-2R)
The immunotoxin denileukin diftitox (Ontak; Eisai Inc.) 
is a recombinant protein attached to the diphtheria toxin 
Table 2 Preclinical agents in CLL
Drug Oncogene or antigen Mechanism of action Developmental phase Study
ABT-737 Bak/Bax Restores apoptosis Phase i/ii van Delft et al16
A-443654 Akt Restores apoptosis Phase i de Frias et al100
Geldanamycin Hsp 90 Restores apoptosis Phase i Lin et al107
Mapatumumab TRAiL Restores apoptosis Phase i Natoni et al80
TRU-016 CD37 ADCC Phase i Furman et al61
XmAb5574 CD19 ADCC Phase i Awan et al60
Abbreviations: ABT-737, isomer of gossypol; Akt, protein kinase; Hsp 90, heat shock protein; TRAiL, tumor necrosis factor related ligand; XmAb5574, anti-CD19 
monoclonal antibody; ADCC, antibody-dependent cellular cytotoxicity; CLL, chronic lymphocytic leukemia.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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along with IL-2 targeting mAb. The antitumor activity is 
mainly mediated by binding to IL-2 receptors and releasing 
the diphtheria toxin. Denileukin diftitox has shown clinical 
efficacy in hematological malignancies and has been 
approved for the treatment of T-cell lymphomas.70 Frankel 
et al reported the activity of denileukin diftitox in relapsed 
CLL patients with CD25 expression of .20%.71 Patients 
were treated with daily infusion of denileukin diftitox at   
18 µg/kg/day for 5 days every 21 days for eight cycles. 
Of a total of 30 treated patients, 22 exhibited 73% CD25 
expression on at least 20% of circulating cells. Patients had 
received a median of four prior treatments (range 1–11). 
The treatment was well tolerated with important toxicities 
reported as asymptomatic elevation of transaminases (17), 
fever (11), fatigue (11), hypoalbuminemia (10), nausea and 
vomiting (7), myalgias (4), rash (4), anorexia (2), vascular 
leak syndrome (2), elevated creatinine (1), and anaphylactic 
reaction (1). Patients on denileukin diftitox demonstrated 
PR of 8%, 50% showing minimal response.71 Morgan et al 
reported activity of denileukin diftitox in relapsed CLL 
patients irrespective of CD25 status. Seven patients with 
refractory CLL and CD25 negative status were treated with 
Ontak on the standard regimen of 18 µg/kg intravenously 
for 5 days repeated every 3 weeks or every 21 days. All 
patients experienced some toxicities such as serositis, 
hypoalbuminemia and asthenia. This study showed activity 
in heavily pretreated CLL patients with two objective PR and 
two minimal responses (Table 1).72
Targeting the death receptor TRAIL
Death receptors have also been targeted to induce apoptosis 
in hematological malignancies. Apoptosis 2 TNF-related 
apoptosis-inducing ligand (Apo2/TRAIL) is a protein 
ligand in the TNF family which binds to the death receptors 
TRAIL-R1 and TRAIL-R2. Along with Fas, TNF-α is the 
key component of extrinsic apoptotic cell death pathways. 
The extrinsic pathway is activated once the ligands bind 
to the death receptors and assemble the death-inducing 
signaling complex on the cell surface, which transmits the 
signals necessary to initiate apoptosis.73 CLL and other B cell 
malignancies are noted to demonstrate resistance to TRAIL 
due to possible lack of functional receptor or overexpression 
of inhibitory molecules.74–76 Apo2/TRAIL is a homodimeric 
protein ligand of the tumor necrosis factor (TNF) family that 
binds to the death receptors TRAIL-R1 and TRAIL-R2 to 
activate extrinsic apoptotic death pathways. Mapatumumab 
has shown in vitro efficacy in different hematological 
malignancies.77,78 Mapatumumab has also shown efficacy in 
patients with NHL.79 In a phase II study of pretreated NHL 
patients (n = 40), mapatumumab was administered at 3 mg/
kg or 10 mg/kg intravenously every 21 days for a total of 
six cycles. Mapatumumab treatment resulted in 8% ORR 
(1 CR, 2 PR) in the follicular lymphoma subgroup, with 
only stabilization of disease in other subgroups. Overall, 
mapatumumab was reported to be well tolerated. Additionally, 
anti-TRAIL antibodies are also showing synergistic effects 
with other agents such as histone deacetylase inhibitors, 
which in turn have been shown to enhance sensitivity of 
CLL cells against TRAIL receptors.74,80 Preclinical studies 
with histone deacetylase inhibitors such as depsipeptide and 
trichostatin A are noted to induce apoptosis by increasing 
sensitivity of malignant cells to TRAIL by causing increased 
expression of death receptors and a decrease in expression of 
inhibitory proteins such as c-FLIP, c-IAP2, and XIAP.81–83 The 
utility of compounds working on the death ligand in cancer 
therapy may become another potential option to overcome 
antiapoptotic effects, which are noted to cause resistance to 
the current treatment (Table 2).
Targeting BCR-mediated signaling
BCR is crucial in CLL biology due to association with 
downstream signaling pathways such as PI3K, Akt, 
and proteins like RAS and MAP kinases. It has been 
demonstrated that interaction between CLL cells and 
lymph node microenvironment regulates proliferation of 
CLL cells through chemokine-induced BCR signaling and 
NFκB activation through canonical pathways resulting 
in c-myc activation.84 BCR signaling is mediated through 
phosphorylation of spleen tyrosine kinase in normal and 
malignant B cells. The spleen tyrosine kinase inhibitor 
fostamatinib has been evaluated in patients with recurrent 
NHL including CLL.85 Fostamatinib was administered orally 
at 200 mg or 250 mg twice daily dosing schedule in the phase 
I and at 200 mg twice daily schedule in the phase II portion 
of the study. Therapy was continued for 4 weeks and the dose 
limiting toxicities reported were diarrhea, neutropenia, and 
thrombocytopenia. In the phase II cohort ORR was 55% and 
6/11 patients with CLL demonstrated a PR. Median duration 
of response was 6.5 months. Important toxicities reported 
include grade 3 and 4 anemia (7%), neutropenia (18%), and 
thrombocytopenia (3%).85 Tyrosine kinase inhibitors such as 
dasatinib and imatinib have changed the paradigm of treatment 
for chronic myeloid leukemia. Preclinical work with dasatinib 
in CLL appears promising and showed induction of apoptosis 
by inhibiting Akt and MAP kinase pathways. However this 
has not been translated into clinical care of patients to date.86,87 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Ongoing research promises to further explore the role of 
tyrosine kinase inhibitors in CLL.
Targeting intracellular proteins
Bcl-2 inhibitors
The Bcl-2 family comprises a group of proteins involved 
in the regulation of programmed cell death by modulating 
the mitochondrial membrane permeability in apoptosis. 
The Bcl-2 family is comprised of anti- and propapoptotic 
proteins functioning to preserve the mitochondrial 
integrity or promoting the release of cytochrome C from 
the mitochondrial membrane. The members of this family 
mirror each other in the homology domains (BH 1–4) and 
proteins are subdivided into three major classes. Functionally, 
members of the Bcl-2 family can be divided into the 
antiapoptotic (Bcl-2, Bcl-xl) and proapoptotic proteins (Bax, 
Bak, and the BH3). Increased Bcl-2 expression is observed 
in B cell malignancies including CLL and is associated with 
resistance to apoptosis.12,88 Clinically, this translates into 
aggressive disease and chemotherapy resistance. Elimination 
of Bcl-2 has the potential to facilitate cancer cell destruction 
and offers a viable therapeutic strategy.89 Several compounds 
are being investigated in clinical trials with the intent of 
inducing apoptosis by either activating the proapoptotic 
proteins or negating the antiapoptotic proteins. Some of these 
compounds include oblimersen sodium, HA14–1, obatoclax 
mesylate, AT-101, and ABT-737.90
Oblimersen sodium is an antisense oligonucleotide 
that is comprised of a short sequence of single stranded 
deoxyribonucleic acids complementary to the Bcl-2 mRNA. 
Oblimersen has shown efficacy in CLL as well as other 
malignancies.14,91 In a phase I/II study, relapsed patients 
with CLL were given continuous infusion of oblimersen 
3–7 mg/kg/day for a total of 5 days for the first cycle and 
7 days for subsequent cycles. The dose limiting toxicity was 
cytokine release syndrome manifested by fever, rigors, and 
low blood pressure. The ORR was 8% but .50% of patients 
demonstrated a notable decrease in spleen size, lymph nodes, 
and liver and/or lymphocyte counts. Subsequently in a 
randomized phase III study oblimersen plus FC chemotherapy 
was compared with FC chemotherapy alone in relapsed CLL 
patients. A total of 241 patients were randomly assigned 
to oblimersen plus FC chemotherapy group (n = 120) or 
chemotherapy-only group (n = 121). Both groups were 
balanced for clinical characteristics. The chemotherapy-only 
group received fludarabine 25 mg/m2/day intravenously 
followed by cyclophosphamide 250 mg/m2/day intravenously 
on days 1–3 of the treatment cycle. In the oblimersen group, 
oblimersen 3 mg/kg/day was administered on days 1 through 
7 by continuous infusion and FC was administered at the 
doses described above on days 5, 6, and 7 every 28 days 
for up to 6 cycles. Important reported toxicities include 
grade 4 neutropenia (7%) and (11%) in the oblimersen 
and chemotherapy group versus chemotherapy-only group, 
respectively. Other toxicities included febrile neutropenia, 
hypotension, and thrombocytopenia seen among 2% of 
patients in both groups, although they were more common in 
the oblimersen plus chemotherapy group. The study reported 
a 17% CR/nodular PR rate in the oblimersen group whereas 
this rate was only 7% in the chemotherapy-only group 
(P = 0.025). Thus oblimersen appears to enhance efficacy of 
the chemotherapeutics fludarabine and cyclophosphamide. 
The important factor in determining response was sensitivity 
to fludarabine treatment, which appears to enhance the 
efficacy by fourfold.91 Most importantly, long-term follow-up 
demonstrated survival advantage in favor of patients receiving 
the Bcl-2 targeted therapy in combination with chemotherapy 
vs chemotherapy alone.
Obatoclax mesylate (GX15–070) is a synthetic pan 
Bcl-2 inhibitor shown to facilitate apoptosis by activation 
of Bax and Bak protein in patients with CLL.15,92,93 In a 
phase I study of relapsed CLL, patients (n = 26) with a 
median of four treatments were enrolled for treatment with 
obatoclax mesylate. Obatoclax mesylate was administered at 
doses ranging from 3.5 to 14 mg/m2 as 1-hour infusion and 
from 20–40 mg/m2 as 3-hour infusion every 3 weeks for a 
total of 74 cycles. MTD was 28 mg/m2 over 3 hours every 
3 weeks. Dose limiting toxicities were neurological and 
included euphoria, somnolence, and ataxia. PR was 4% and 
several patients demonstrated hematological improvements 
(3/11 with anemia and 4/14 with thrombocytopenia), and 
lymphocyte reduction was observed in 18/26 patients.15 
This compound holds promise and is continually being 
investigated in patients with CLL.
AT-101 is an orally available BH3 mimetic that has been 
demonstrated to induce apoptosis in CLL cell in vitro.94 
AT-101 has demonstrated clinical efficacy and favorable 
toxicity as a single agent in treatment-naïve high-risk patients 
with CLL. James et al evaluated efficacy of AT-101 in a 
phase I clinical trial with treatment-naïve high-risk CLL, in 
which a total of seven patients were treated with AT-101 at 
doses ranging from 20 to 40 mg daily.95 Important patient 
characteristics included: median age 55 years, elevated 
ZAP-70 (57%), elevated CD38 (71%), unmutated IgVH 
(57%), trisomy 12 (43%), and del(17p) (43%). AT-101 
demonstrated antileukemic activity as evidenced by 5/6 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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patients showing decrease in lymphocyte count, 6/6 having 
reduced lymphadenopathy, and 5/5 having palpable spleens 
with a reduction in spleen size. The most common adverse 
event reported was incidence of grade 3 elevation of 
transaminases among six patients. It was concluded that 
AT-101 was safe, with antileukemic activity among high-risk 
patients with CLL.95 AT-101 in combination with rituximab 
has been reported to exhibit enhanced cytotoxicity in CLL 
cells.94,96 In relapsed refractory CLL, AT-101 has yielded 
an ORR of 38%.96 The treatment was well tolerated except 
for toxicities as manifested by paralytic ileus, fatigue, and 
neutropenia.
ABT-737 is an isomer of gossypol with the ability to 
target the Bcl-2 and induce apoptosis in preclinical models 
of B cell cancers (Table 2). The analog of ABT-737, ABT-
263, is currently being investigated in the clinic and has 
also demonstrated activity against CLL cells in vitro.16,97 
The earlier Bcl-2 inhibitors have demonstrated modest 
efficacy in cancer therapy, but the potential for newer pan 
Bcl-2 inhibitors appears promising due to improved target 
binding, bioavailability, and route of administration. ABT-
263 is currently evaluated in clinical trials for patients with 
lymphoid malignancies including CLL. In a phase I/II 
clinical study with relapsed CLL, two dosing schedules were 
evaluated of ABT-263 (intermittent dosing on days 1–14 of 
a 21-day schedule vs continuous dosing 21 days of a 21-day 
cycle). Responses among the 27 CLL patients included 
PR in 11% of patients, whereas 22% exhibited .50% 
decrease in lymphocyte counts for .2 months and 40% of 
patients demonstrated stable disease. The important reported 
toxicities include dose-dependent thrombocytopenia due to 
target inhibition of Bcl-xl.98
Akt inhibitors
Protein, serine, and threonine kinases comprise several 
families of transmembrane and cytoplasmic receptors 
(receptor protein tyrosine kinases). The PI3 K pathway is an 
important cell survival route, which is aberrantly expressed 
in CLL. The PI3 K pathway activates the Akt/protein kinase 
B by phosphorylation. Akt, once activated, inhibits apoptosis 
by phosphorylating proteins such as Bad and procaspase 9, 
and has also been implicated with NFκβ activation.99 Akt 
inhibitor constitutes an important therapeutic option in the 
arsenal of targeted drug therapy. Preclinical data have shown 
that Akt inhibitors can induce apoptosis in CLL cells. The 
Akt inhibitor A-443654 has been shown to cause an increase 
in levels of the BH3-only proteins NOXA and PUMA and 
a decrease in Mcl-1 levels, independent of p53 function. 
The preclinical activity of these compounds is intriguing, 
with the possibility that the Akt inhibitors can add to the 
class of drugs inducing apoptosis and may complement the 
effects of other molecular targets to provide improve efficacy 
along with adding an option in high-risk patients identified 
by their defective p53 status (Table 2).100 CAL-101 is a PI3 K 
inhibitor currently being evaluated in preclinical studies 
and has been shown to promote apoptosis by abrogation 
of signals transmitted through CD40 L, BAFF, TNFα, and 
fibronectin.101 The results of a phase I study were recently 
reported. CAL-101 was administered orally once or twice 
daily continuously for 28 days for a total of 12 months. The 
important clinical characteristics of patients included median 
age of 65 years (range 37–82), median of five prior therapies, 
29 patients with bulky disease, and 22 patients with adverse 
cytogenetics del(17p) or del(11q). The study reported 
substantial decreases in the size of the lymph nodes, with 
91% of patients showing a >50% decrease in lymph-node 
size. PR was reported in 33% of patients. Median duration 
of response has not been reached. Adverse events reported 
include grade 3 pneumonias (24%), neutropenia (24%), 
thrombocytopenia (11%), and anemia (8%).102 Enzastaurin 
HCL is an oral kinase inhibitor which inhibits signaling 
associated with the PI3 K pathway; a phase I study in CLL 
is currently ongoing and results are awaited.103
Heat shock protein inhibitors
Heat shock proteins (HSP) are a group of cytoplasmic 
proteins essential in maintaining cellular homeostasis by 
virtue of their role in transcriptional regulation, chromatin 
remodeling, and regulation of key signaling pathways such as 
Akt, Raf-1, and ERB-2.104 HSP also assist with the folding of 
mitochondrial proteins and regulate proteolytic degradation 
of misfolded protein in an ATP-dependent manner.105 HSP 
and the helper protein known as the co-chaperon form a 
network which acts as a guardian for several oncoproteins 
facilitating tumor growth by regulating survival signal and 
inducing resistance to chemotherapy. Mammalian HSP are 
classified and named according to their molecular sizes into 
six families.105
Drugs targeting HSP are being evaluated in different 
malignancies. The ansamycin antibiotics geldanamycin and 
herbimycin A have demonstrated antileukemic activity.106 
The exact mechanism of action of HSP is currently being 
explored in CLL but it has been suggested that this group 
exerts its effects possibly through depletion of Akt causing 
loss of survival signals, changes in p53 and p21, or depletion 
of ZAP-70 causing inhibition of prosurvival signals.107 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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In preclinical studies, the HSP inhibitor geldanamycin has 
shown induction of cell apoptosis irrespective of p53/ATM 
mutation status, suggesting a role in high-risk patients. The 
validation of preclinical activity of these compounds awaits 
results from clinical trials (Table 2).
Cyclin-dependent kinase inhibitors
Cyclin-dependent kinases (CDK) are important regulators 
of the cell cycle that controls transcription in different 
hematological malignancies. CDK inhibitors including 
alvocidib and SNS-032 have shown activity in CLL. 
Alvocidib (NSC649890) is derived from a plant and has 
shown substantial cytotoxicity on CLL cells in vitro.108 
Alvocidib inhibits the antiapoptotic proteins including 
the Mcl-1, X-linked inhibitor of apoptosis, additionally 
inhibits the transcription by abrogating the functions 
of CDK9 and CDK7. In a phase I study alvocidib was 
administered as a 30-minute loading dose followed by 4-hour 
infusion administered weekly for 4 of 6 weeks in patients 
with refractory CLL.109 The study included 42 patients with 
refractory CLL in three cohorts. Alvocidib was administered 
as a 30 mg/m2 loading dose followed by 30 mg/m2 4-hour 
infusion in cohort 1; cohort 2, alvocidib 40 mg/m2 followed 
by 40 mg/m2 4-hour infusion; cohort 3, alvocidib 30 mg/m2 
loading dose followed by 30 mg/m2 4-hour infusion for 
treatments 1–4 then a 30 mg/m2 loading dose followed 
by 50 mg/m2 infusion. The dose limiting toxicity was 
hyperacute tumor lysis syndrome. In order to prevent tumor 
lysis aggressive prophylaxis and selection of patients with 
leukocyte count of ,200 × 109/L were taken which permitted 
dosing on cohort 3. Out of the 42 treated patients PR was 
achieved in 45%, and median duration of response exceeded 
12 months. Responses were also observed in the high-risk 
group; 42% of the del(17p) and 72% of del(11q) patients 
demonstrated response.109 These results were validated 
in a multicenter international trial. This study included 
patients with fludarabine-refractory CLL or prolymphocytic 
leukemia. The important characteristics included median 
age of 61 years, 81% of patients with Rai stage III/IV , and 
65% of patients with bulky lymphadenopathy, and adverse 
cytogenetics del(17p) or del(11q) were noted among 31% 
and 36% of patients, respectively. Alvocidib was given 
intravenously with an initial bolus of 30 mg/m2 followed 
by continuous infusion of 30 mg/m2 over 4 hours; in the 
absence of tumor lysis 50 mg/m2 over 4 hours continuous 
infusion was administered once weekly for 4 weeks followed 
by a 2-week break for a total of six cycles. Adverse events 
included grade 3 febrile neutropenia (15%), infections (32%), 
diarrhea (17%), and tumor lysis syndrome (19%). Eight 
patients required hemodialysis for renal failure secondary to 
tumor lysis syndrome. The study reported responses, mainly 
PR, among 21 patients (31%) using NCI-96 criteria and 17 
patients (25%) using the hybrid criteria. Median duration 
of response was 12.2 months for the responders. Responses 
among the high-risk group identified with del(17p13.1) were 
25% and 19%, with del(11q22.3) responses were 30% and 
20%, and with bulky lymphadenopathy responses 39% and 
32% using the NCI-96 and hybrid criteria, respectively.110
SNS-032 is a selective inhibitor of CDKs 2, 7, and 9. In a 
phase I dose escalation study in relapsed CLL, SNS-032 was 
given at 22–100 mg/m2. Tumor lysis syndrome was observed 
in four patients treated at 75 mg/m2 and one patient treated 
with 100 mg/m2; however none of the patients required 
dialysis and there were no deaths from the treatment. Other 
toxicities included QTc prolongation in nine patients with 
CLL; myelosuppression was also observed but was more 
pronounced in patients with myeloma. MTD for CLL was 
75 mg/m2, one patient demonstrating .50% reduction in 
measurable disease.111
Targeting the DNA
Bendamustine
Bendamustine is a traditional alkylating agent, which has 
emerged as an effective therapy in lymphoproliferative 
disorders including CLL. Bendamustine acts primarily 
through the formation of intra-stand and inter-stand 
crosslinking between DNA bases resulting in inhibition of 
DNA replication, repair, and transcription. Bendamustine 
has recently been approved for the treatment of CLL based 
on a randomized trial in comparison with chlorambucil.112 In 
the pivotal study of previously untreated CLL, patients were 
treated with bendamustine (n = 162) 100 mg/m2 intravenously 
on days 1 and 2 every 4 weeks or chlorambucil (n = 157) 
0.8 mg/kg orally on day 1 and 15 or as divided doses on days 
1 to 2 and 15 to 16 in some cases of a 28-day cycle for a 
total of 6 cycles. ORR with bendamustine and chlorambucil 
was 68% and 31% (P , 0.0001), respectively, with a CR 
of 31% and 2%, respectively. Median progression free 
survival was 21.6 months and 8.3 months with bendamustine 
and chlorambucil (P , 0.0001), respectively. Overall the 
treatment with bendamustine was well tolerated except 
for more myelosuppression, although the rate of infectious 
complications was similar.113 Bendamustine in combination 
with rituximab has also been used for upfront treatment in 
CLL. Bendamustine has also been combined with other 
targeted therapies such as rituximab. In a phase II study, a OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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total of 117 patients were recruited, and bendamsutine was 
given at 90 mg/m2 on days 1 and 2 and rituximab 375 mg/m2 
on cycle 1 and 500 mg/m2 on the subsequent cycles. Treatment 
cycles were repeated every 28 days for a total of six cycles. 
ORR was 90.9% with a CR of 32.7%.114
Summary
Improved understanding of the biology of CLL has resulted in 
identification of novel therapeutic targets for tumor cells and 
their microenvironment. This has resulted in development 
of therapeutics with the ability to selectively target disease-
defining pathological processes. Exploitation of these targets 
has already started to demonstrate disease-modifying effects, 
with improvement in clinical responses as well as survival 
outcomes. The most robust data validating the evolving yet 
promising role of target specific therapies are for rituximab, 
for which combination chemotherapy strategies have clearly 
improved disease responsiveness and advantage in survival 
outcome of patients with CLL. Similarly, the ability to tar-
get intracellular pathways associated with drug resistance 
and clinical aggressive disease has rejuvenated the CLL 
therapeutic arena. In this context Bcl-2, CDK, and other 
potential intracellular targets continue to hold promise with 
the availability of more patient-convenient and target-specific 
molecules. Lastly, the recent introduction of immunomodu-
lating agents has added another critical dimension to targeted 
therapeutics, with their ability to interrupt microenvironmen-
tal signals contributing to leukemic cell survival.
Thus the armamentarium of targeted treatment in CLL is 
growing at a steady pace with promising impact in the very 
near future (Tables 2, 3). While different compounds are now 
available to target critical oncogenic pathways, the challenge 
lies in identifying the ideal target based on the molecular 
profile of the tumor cell, especially considering the clinical 
heterogeneity of CLL. Ongoing research continues to focus 
on optimizing therapeutic strategies based on molecular 
profiles of subsets of CLL patients as well as concentrating 
on developing combinations regimens engaging a multitar-
geted approach.
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